DataMEDS AI Reports $2.7 Million Third-Quarter Revenue and $2.72 Net Profit Per Share
DataMEDS AI reported third-quarter 2026 revenue of $2.7 million and net profit per share of $2.72, while outlining developments involving Corexa Pharmacy, Helomics and its Health Lives Here app.
DataMEDS AI, Inc. (NASDAQ:MEDS) reported third-quarter 2026 revenue of $2.7 million, compared with $1.8 million in the second quarter of 2026. The company said the increase was primarily linked to higher drug-dispensing activity at Corexa Pharmacy.
For the quarter ended September 30, 2026, DataMEDS AI recorded a net operating profit of $10.535 million. That compares with a net operating loss of $34.318 million for the quarter ended September 30, 2025.
The company attributed the change largely to the extinguishment of debt and outstanding liabilities connected with litigation involving prior management. It also cited lower management compensation expenses and reduced general and administrative expenses.
Net profit per share was $2.72 based on 3.961 million weighted average shares outstanding. In the quarter ended September 30, 2025, the company reported a loss of $23.07 per share based on 1.488 million weighted average shares outstanding.
DataMEDS AI launched the Health Lives Here mobile application in partnership with the NFL Alumni Health marketing platform. The company said the app provides Corexa Pharmacy with a channel to reach customers for FDA-approved GLP-1 medications and Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies.
The application incorporates DataMEDS AI’s EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform. Corexa Pharmacy provides dispensing and related pharmacy services, including distribution of products developed by Tollo Health.
In October 2026, DataMEDS AI obtained an exclusive licence to the REBOOT GLP-1 patient management platform and related intellectual property. The company said the licence covers patented, AI-assisted patient management services that it believes can support customer acquisition and long-term customer value.
Corexa Pharmacy also launched compounded peptides in November 2026 under the FDA’s Enforcement Discretion Policy published in the Federal Register on October 30, 2026. DataMEDS AI described the offering as an incremental revenue opportunity.
Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. The company also identified compliance with the policy and state pharmacy laws as risks, including the possibility that the policy could be changed or withdrawn.
In November 2026, DataMEDS AI signed a non-binding memorandum of understanding with a Florida-based HMO to deploy the Health Lives Here app to its 25,000+ members. The company said the arrangement would provide an institutional customer base for its per-member-per-month model.
Definitive agreements are expected in the fourth quarter of 2026. However, DataMEDS AI stated that the memorandum is non-binding and that definitive agreements may not be executed on the expected timeline or at all.
DataMEDS AI acquired Helomics Corporation in September 2026. Helomics is a Pittsburgh-based CLIA-certified cancer diagnostics laboratory focused on the ChemoFx® Assay, a proprietary chemotherapy-selection diagnostic test.
Humana’s South Carolina Medicaid coverage policy for the ChemoFx® Assay took effect on July 22, 2026. DataMEDS AI said the policy adds a proprietary revenue stream, while the laboratory’s 70,000+ primary tumor biopsies create drug discovery opportunities.
The company said it is expanding Helomics’ test menu to serve patient groups beyond cancer, particularly GLP-1 patients. It also identified the integration of Helomics, ChemoFx testing volumes and reimbursement as areas subject to uncertainty.
DataMEDS AI said it regained full compliance with Nasdaq listing standards, including the net equity requirement, on October 19, 2026.
The company cautioned that its forward-looking statements are based on management’s current expectations and are not predictions of actual performance. It identified additional risks involving demand for GLP-1 medications and Forzet™, healthcare-law compliance, liquidity, capital resources and the ability to fund operations.
DataMEDS AI announced financial results for the third quarter ended September 30, 2026, alongside a business update. The company reported third-quarter revenue of $2.7 million and net profit per share of $2.72.
DataMEDS AI reported third-quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter of 2026. The company said the increase was primarily driven by growth in Corexa Pharmacy drug dispensing.
DataMEDS AI recorded a net operating profit of $10.535 million in the quarter ended September 30, 2026, compared with a net operating loss of $34.318 million in the quarter ended September 30, 2025. The company attributed the change largely to the extinguishment of debt and outstanding liabilities related to litigation associated with prior management, lower management compensation expenses and reduced general and administrative expenses.
DataMEDS AI reported net profit per share of $2.72 for the quarter ended September 30, 2026, based on 3.961 million weighted average shares outstanding. This compared with a loss of $23.07 per share and 1.488 million weighted average shares outstanding in the quarter ended September 30, 2025.
DataMEDS AI is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. It incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application, while its Corexa Health subsidiary provides pharmacy dispensing and related services and it owns Helomics Corporation, a commercial clinical molecular diagnostics laboratory.
The Health Lives Here mobile application, partnered with the NFL Alumni Health marketing platform, gives Corexa Pharmacy a customer acquisition channel for dispensing FDA-approved GLP-1 medications and Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies. The company said the app is incorporated with its EinsteinRx™ and PharmacyChain™ platforms.
DataMEDS AI said it obtained an exclusive licence to the REBOOT GLP-1 patient management platform and related intellectual property in October 2026. The company believes the patented, AI-assisted patient management services support scaling customer acquisition and increasing long-term customer value.
Corexa Pharmacy launched compounded peptides in November 2026 under the FDA's Enforcement Discretion Policy published in the Federal Register on October 30, 2026. DataMEDS AI described this as an incremental revenue opportunity, while also stating that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety or efficacy.
DataMEDS AI signed a non-binding memorandum of understanding with a Florida-based HMO in November 2026 to deploy the Health Lives Here app to its 25,000+ members. Definitive agreements are expected in the fourth quarter of 2026, but the company said the memorandum is non-binding and that definitive agreements may not be executed on the expected timeline or at all.
DataMEDS AI acquired Helomics Corporation in September 2026; Helomics is a Pittsburgh-based CLIA-certified cancer diagnostics laboratory. The company said Humana's South Carolina Medicaid coverage policy for the proprietary ChemoFx® Assay, effective July 22, 2026, adds an incremental proprietary revenue stream, while Helomics' biobank of 70,000+ primary tumour biopsies creates drug discovery opportunities.
DataMEDS AI said it is adding additional testing services to Helomics' test menu so the laboratory can support patient groups beyond cancer, especially GLP-1 patients. The company also said the acquisition opens the cancer pharmaceuticals market for Corexa Pharmacy and adds traditional laboratory services revenue.
DataMEDS AI said it regained full compliance with Nasdaq listing standards, including the net equity requirement, on October 19, 2026. The company is identified in the announcement as DataMEDS AI, Inc. (NASDAQ:MEDS), and its company description also gives the listing as (NASDAQ: MEDS).
Gerald Commissiong, Interim Co-CEO of DataMEDS AI, said continued growth was expected for the fourth quarter based on steps taken to add medical foods and diagnostic laboratory tests related to patients receiving prescriptions from Corexa Pharmacy. The company also said its forward-looking statements are based on management's current expectations and are not predictions of actual performance.
DataMEDS AI identified risks including changes to or withdrawal of the FDA's Enforcement Discretion Policy, compliance with state pharmacy laws, the non-binding HMO memorandum of understanding, integration of Helomics, demand for GLP-1 medications and Forzet™, compliance with healthcare laws, maintaining Nasdaq compliance, and the company's liquidity, capital resources and ability to fund operations. The company cautioned that actual results may differ materially from its forward-looking statements and referred readers to its SEC filings and risk factors.